Cargando…

Inequities in Treatments and Outcomes Among Patients Hospitalized With Hypertrophic Cardiomyopathy in the United States

BACKGROUND: Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiac disease. In small studies, sociodemographic factors have been associated with disparities in septal reduction therapy, but little is known about the association of sociodemographic factors with HCM treatments and outc...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, Daniel Y., Waken, R. J., Fox, Daniel K., Hammond, Gmerice, Joynt Maddox, Karen E., Cresci, Sharon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10382014/
https://www.ncbi.nlm.nih.gov/pubmed/37232238
http://dx.doi.org/10.1161/JAHA.122.029930
_version_ 1785080587236671488
author Johnson, Daniel Y.
Waken, R. J.
Fox, Daniel K.
Hammond, Gmerice
Joynt Maddox, Karen E.
Cresci, Sharon
author_facet Johnson, Daniel Y.
Waken, R. J.
Fox, Daniel K.
Hammond, Gmerice
Joynt Maddox, Karen E.
Cresci, Sharon
author_sort Johnson, Daniel Y.
collection PubMed
description BACKGROUND: Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiac disease. In small studies, sociodemographic factors have been associated with disparities in septal reduction therapy, but little is known about the association of sociodemographic factors with HCM treatments and outcomes more broadly. METHODS AND RESULTS: Using the National Inpatient Survey from 2012 to 2018, HCM diagnoses and procedures were identified by International Classification of Diseases, Ninth/Tenth Revision, Clinical Modification (ICD‐9‐CM and ICD‐10‐CM) codes. Logistic regression was used to determine the association of sociodemographic risk factors with HCM procedures and in‐hospital death, adjusting for clinical comorbidities and hospital characteristics. Of 53 117 patients hospitalized with HCM, 57.7% were women, 20.5% were Black individuals, 27.7% lived in the lowest zip income quartile, and 14.7% lived in rural areas. Among those with obstruction (45.2%), compared with White patients, Black patients were less likely to undergo septal myectomy (adjusted odds ratio [aOR], 0.52 [95% CI, 0.40–0.68]), or alcohol septal ablation (aOR, 0.60 [95% CI, 0.42–0.86]). Patients with Medicaid were less likely to undergo each procedure (aOR, 0.78 [95% CI, 0.61–0.99] for myectomy; aOR, 0.54 [95% CI, 0.36–0.83] for ablation). Women (aOR, 0.66 [95% CI, 0.58–0.74]), patients with Medicaid (aOR, 0.78 [95% CI, 0.65–0.93]), and patients from low‐income areas (aOR, 0.77 [95% CI, 0.65–0.93]) were less likely to receive implantable cardioverter‐defibrillators. Women (aOR, 1.23 [95% CI, 1.10–1.37]) and patients from towns (aOR, 1.16 [95% CI, 1.03–1.31]) or rural areas (aOR, 1.57 [95% CI, 1.30–1.89]) had higher odds of in‐hospital death. CONCLUSIONS: Among 53 117 patients hospitalized with HCM, race, sex, social, and geographic risk factors were associated with disparities in HCM outcomes and treatment. Further research is required to identify and address the sources of these inequities.
format Online
Article
Text
id pubmed-10382014
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-103820142023-07-29 Inequities in Treatments and Outcomes Among Patients Hospitalized With Hypertrophic Cardiomyopathy in the United States Johnson, Daniel Y. Waken, R. J. Fox, Daniel K. Hammond, Gmerice Joynt Maddox, Karen E. Cresci, Sharon J Am Heart Assoc Original Research BACKGROUND: Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiac disease. In small studies, sociodemographic factors have been associated with disparities in septal reduction therapy, but little is known about the association of sociodemographic factors with HCM treatments and outcomes more broadly. METHODS AND RESULTS: Using the National Inpatient Survey from 2012 to 2018, HCM diagnoses and procedures were identified by International Classification of Diseases, Ninth/Tenth Revision, Clinical Modification (ICD‐9‐CM and ICD‐10‐CM) codes. Logistic regression was used to determine the association of sociodemographic risk factors with HCM procedures and in‐hospital death, adjusting for clinical comorbidities and hospital characteristics. Of 53 117 patients hospitalized with HCM, 57.7% were women, 20.5% were Black individuals, 27.7% lived in the lowest zip income quartile, and 14.7% lived in rural areas. Among those with obstruction (45.2%), compared with White patients, Black patients were less likely to undergo septal myectomy (adjusted odds ratio [aOR], 0.52 [95% CI, 0.40–0.68]), or alcohol septal ablation (aOR, 0.60 [95% CI, 0.42–0.86]). Patients with Medicaid were less likely to undergo each procedure (aOR, 0.78 [95% CI, 0.61–0.99] for myectomy; aOR, 0.54 [95% CI, 0.36–0.83] for ablation). Women (aOR, 0.66 [95% CI, 0.58–0.74]), patients with Medicaid (aOR, 0.78 [95% CI, 0.65–0.93]), and patients from low‐income areas (aOR, 0.77 [95% CI, 0.65–0.93]) were less likely to receive implantable cardioverter‐defibrillators. Women (aOR, 1.23 [95% CI, 1.10–1.37]) and patients from towns (aOR, 1.16 [95% CI, 1.03–1.31]) or rural areas (aOR, 1.57 [95% CI, 1.30–1.89]) had higher odds of in‐hospital death. CONCLUSIONS: Among 53 117 patients hospitalized with HCM, race, sex, social, and geographic risk factors were associated with disparities in HCM outcomes and treatment. Further research is required to identify and address the sources of these inequities. John Wiley and Sons Inc. 2023-05-26 /pmc/articles/PMC10382014/ /pubmed/37232238 http://dx.doi.org/10.1161/JAHA.122.029930 Text en © 2023 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research
Johnson, Daniel Y.
Waken, R. J.
Fox, Daniel K.
Hammond, Gmerice
Joynt Maddox, Karen E.
Cresci, Sharon
Inequities in Treatments and Outcomes Among Patients Hospitalized With Hypertrophic Cardiomyopathy in the United States
title Inequities in Treatments and Outcomes Among Patients Hospitalized With Hypertrophic Cardiomyopathy in the United States
title_full Inequities in Treatments and Outcomes Among Patients Hospitalized With Hypertrophic Cardiomyopathy in the United States
title_fullStr Inequities in Treatments and Outcomes Among Patients Hospitalized With Hypertrophic Cardiomyopathy in the United States
title_full_unstemmed Inequities in Treatments and Outcomes Among Patients Hospitalized With Hypertrophic Cardiomyopathy in the United States
title_short Inequities in Treatments and Outcomes Among Patients Hospitalized With Hypertrophic Cardiomyopathy in the United States
title_sort inequities in treatments and outcomes among patients hospitalized with hypertrophic cardiomyopathy in the united states
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10382014/
https://www.ncbi.nlm.nih.gov/pubmed/37232238
http://dx.doi.org/10.1161/JAHA.122.029930
work_keys_str_mv AT johnsondaniely inequitiesintreatmentsandoutcomesamongpatientshospitalizedwithhypertrophiccardiomyopathyintheunitedstates
AT wakenrj inequitiesintreatmentsandoutcomesamongpatientshospitalizedwithhypertrophiccardiomyopathyintheunitedstates
AT foxdanielk inequitiesintreatmentsandoutcomesamongpatientshospitalizedwithhypertrophiccardiomyopathyintheunitedstates
AT hammondgmerice inequitiesintreatmentsandoutcomesamongpatientshospitalizedwithhypertrophiccardiomyopathyintheunitedstates
AT joyntmaddoxkarene inequitiesintreatmentsandoutcomesamongpatientshospitalizedwithhypertrophiccardiomyopathyintheunitedstates
AT crescisharon inequitiesintreatmentsandoutcomesamongpatientshospitalizedwithhypertrophiccardiomyopathyintheunitedstates